Related Experiment Video
Updated: Apr 3, 2026
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
United States Food and Drug Administration Regulation of Gene and Cell Therapies
Alexander M Bailey1, Judith Arcidiacono2, Kimberly A Benton2
1Office of Cellular, Tissue, and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), United States Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. alexander.bailey@fda.hhs.gov.
Abstract:
The United States (US) Food and Drug Administration (FDA) is a regulatory agency that has oversight for a wide range of products entering the US market, including gene and cell therapies. The regulatory approach for these products is similar to other medical products within the United States and consists of a multitiered framework of statutes, regulations, and guidance documents. Within this framework, there is considerable flexibility which is necessary due to the biological and technical complexity of these products in general. This chapter provides an overview of the US FDA regulatory oversight of gene and cell therapy products.